Teleflex Incorporated (NYSE:TFX) Stock Position Raised by Strs Ohio

Strs Ohio raised its position in shares of Teleflex Incorporated (NYSE:TFX) by 30.1% in the fourth quarter, Holdings Channel reports. The firm owned 154,485 shares of the medical technology company’s stock after buying an additional 35,723 shares during the period. Strs Ohio’s holdings in Teleflex were worth $58,154,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Amundi Pioneer Asset Management Inc. raised its stake in Teleflex by 21.7% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 17,818 shares of the medical technology company’s stock valued at $5,384,000 after purchasing an additional 3,173 shares during the last quarter. LPL Financial LLC acquired a new position in Teleflex in the 2nd quarter valued at about $306,000. Morgan Stanley raised its stake in Teleflex by 4.4% in the 2nd quarter. Morgan Stanley now owns 104,160 shares of the medical technology company’s stock valued at $34,493,000 after purchasing an additional 4,425 shares during the last quarter. CSat Investment Advisory L.P. raised its stake in Teleflex by 97.4% in the 2nd quarter. CSat Investment Advisory L.P. now owns 150 shares of the medical technology company’s stock valued at $50,000 after purchasing an additional 74 shares during the last quarter. Finally, Andra AP fonden raised its stake in Teleflex by 11.5% in the 2nd quarter. Andra AP fonden now owns 14,500 shares of the medical technology company’s stock valued at $4,802,000 after purchasing an additional 1,500 shares during the last quarter. 90.51% of the stock is owned by institutional investors.

Shares of NYSE:TFX traded down $4.93 during trading on Friday, reaching $379.89. 5,788 shares of the stock were exchanged, compared to its average volume of 156,936. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.44 and a current ratio of 2.33. Teleflex Incorporated has a 12-month low of $259.19 and a 12-month high of $389.27. The firm has a market cap of $17.89 billion, a price-to-earnings ratio of 40.42, a price-to-earnings-growth ratio of 2.12 and a beta of 0.95. The firm’s 50-day moving average price is $373.29 and its 200 day moving average price is $351.33.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, October 31st. The medical technology company reported $2.97 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.75 by $0.22. Teleflex had a return on equity of 18.81% and a net margin of 17.36%. The business had revenue of $648.32 million during the quarter, compared to analysts’ expectations of $643.20 million. During the same quarter in the previous year, the business earned $2.52 EPS. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. As a group, equities research analysts forecast that Teleflex Incorporated will post 11.08 EPS for the current year.

In other news, CFO Thomas E. Powell sold 7,500 shares of the business’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $327.42, for a total transaction of $2,455,650.00. Following the completion of the sale, the chief financial officer now owns 18,197 shares in the company, valued at approximately $5,958,061.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Thomas E. Powell sold 5,000 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $348.70, for a total value of $1,743,500.00. Following the sale, the chief financial officer now owns 15,697 shares of the company’s stock, valued at approximately $5,473,543.90. The disclosure for this sale can be found here. Insiders have sold a total of 46,981 shares of company stock valued at $15,912,679 in the last quarter. Company insiders own 2.36% of the company’s stock.

A number of research firms have recently commented on TFX. UBS Group upped their price objective on shares of Teleflex from $415.00 to $430.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Barclays set a $365.00 price objective on shares of Teleflex and gave the company a “hold” rating in a research note on Friday, November 1st. Wells Fargo & Co upped their price objective on shares of Teleflex from $415.00 to $425.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Needham & Company LLC set a $403.00 price objective on shares of Teleflex and gave the company a “buy” rating in a research note on Tuesday, October 15th. Finally, Raymond James dropped their price objective on shares of Teleflex from $420.00 to $415.00 and set a “strong-buy” rating for the company in a research note on Monday, October 7th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $398.60.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Further Reading: Price to Earnings Ratio (PE) Basics

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.